Association Studies of Fcγ Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831
- Citation:
- Cancer Immunol Res vol 2 (10) 962-969
- Year:
- 2014
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Book Volume:
- 4
- Parents:
- 2027
- Children:
- None
- Pharmas:
- Grants:
- U10CA180821, U24CA196171, U10 CA180821, P30 CA015083, R01-CA1520-45, U24 CA196171, CA25224, R01 CA152045, U10 CA025224
- Corr. Author:
- Authors:
- Nadine Norton Rebecca M. Olson Mark Pegram Kathleen Tenner Karla V. Ballman Raphael Clynes Keith L. Knutson Edith A. Perez
- Networks:
- Study
- NCCTG-N9831
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- Breast cancer, HER2, adjuvant trastuzumab, Fc gamma, polymorphism